Ustekinumab (Stelara)

Covers ustekinumab (Stelara) only for FDA‑approved indications—moderate‑to‑severe plaque psoriasis (age ≥12), adult psoriatic arthritis, and adult moderate‑to‑severe Crohn’s disease and ulcerative colitis—and excludes off‑label use. Approval requires meeting indication‑specific prior‑therapy or intolerance/contraindication criteria, prescriber specialty (gastroenterologist for IBD, dermatologist for psoriasis, rheumatologist/dermatologist for PsA), age limits, an IV induction dose within 2 months before SC maintenance for IBD, and documentation of response for reauthorization (initial authorization 3 months; reauthorizations 12 months).

"Stelara is indicated for the treatment of patients 12 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy."

Sign up to see full coverage criteria, indications, and limitations.